

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/H0C9FFF360AEN.html>

Date: November 2018

Pages: 64

Price: US\$ 3,500.00 (Single User License)

ID: H0C9FFF360AEN

Abstracts

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Pipeline Review, H2 2018

SUMMARY

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Hepatitis A virus cellular receptor 2 (HAVCR2) is a protein encoded by the HAVCR2 gene. It inhibits T-helper type 1 lymphocyte (Th1)-mediated auto%li%and alloimmune responses and promotes immunological tolerance. Binding to LGALS9 is proposed to be involved in innate immune response to intracellular pathogens and suppression of T-cell responses the resulting apoptosis of antigen-specific cells implicate HAVCR2 phosphorylation and disruption of its association with BAG6.

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 5, 1, 2 and 5 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology which include indications Solid Tumor, Melanoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Colon Cancer, Endometrial Cancer, Gastric Cancer, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lymphoma, Malignant Mesothelioma, Metastatic Breast Cancer, Metastatic Melanoma, Myelodysplastic Syndrome, Ovarian Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia and Squamous Non-Small Cell Lung Cancer.

The latest report Hepatitis A Virus Cellular Receptor 2 - Pipeline Review, H2 2018, outlays comprehensive information on the Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2)

The report reviews Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics and enlists all their major and minor projects

The report assesses Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create

effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Overview

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Companies Involved in Therapeutics Development

Aurigene Discovery Technologies Ltd

BeiGene Ltd

Bristol-Myers Squibb Co

Eli Lilly and Co

Elpiscience Biopharmaceuticals Co Ltd

F. Hoffmann-La Roche Ltd

GigaGen Inc

Incyte Corp

Interprotein Corp

Jounce Therapeutics Inc

Novartis AG

Symphogen A/S

TESARO Inc

Trellis Bioscience Inc

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain

Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Drug Profiles

BGBA-425 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986258 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CA-170 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CA-327 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ES-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCAGN-2390 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3321367 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGB-453 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies 3 to Inhibit TIM3 for Solid Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit TIM-3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit CD366 for Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RO-7121661 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit TIM-3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sym-023 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit TIM-3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRL-6061 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TSR-022 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Dormant Products

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Product Development Milestones

Featured News & Press Releases

Oct 01, 2018: TESARO announces data presentation on its melanoma drug candidate

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell I...

TSR-022 at the SITC 2018 Annual Meeting

Jul 10, 2018: Selexis provides update on antibody candidate Sym023

Apr 11, 2018: Agenus Presents preclinical data on INCAGN02390 at the American Association for Cancer Research (AACR) 2018 Annual Meeting

Nov 03, 2017: Curis to Present Data On Its Cancer Drug Candidate CA-170 at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit

Nov 03, 2017: Curis to Present Preclinical Data On Its Cancer Drug candidate CA-327 at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit

Sep 11, 2017: Curis and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 2017

Aug 31, 2017: Curis Announces CA-170 Poster Presentation at ESMO 2017 Congress

May 25, 2017: Curis Announces Presentation on CA-170 at 2017 ASCO Annual Meeting

Nov 09, 2016: Curis Presents Early Clinical Pharmacokinetic and Biomarker Data from CA-170's Phase 1 Trial at the SITC 2016 Conference

Oct 11, 2016: Curis Expands Oncology Pipeline with an Oral Small Molecule PD-L1/TIM-3 Immune Checkpoint Antagonist

Aug 08, 2016: Cancer Treatment Centers of America at Western Regional Medical Center is the first site in the world for new investigational anti-cancer treatment

Jun 04, 2016: TESARO Provides Update on TSR-022 at ASCO Investor Briefing

Jun 01, 2016: Curis Announces FDA Acceptance of Investigational New Drug Application for CA-170, the First Orally Available Small Molecule to Target and Inhibit Immune Checkpoints

Apr 25, 2016: Tesaro Announces Submission Of Investigational New Drug Application For ANTI-TIM-3 Antibody TSR-022 To The US FDA

Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CA-170 and PD-L1/TIM-3 Antagonist at AACR Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Aurigene Discovery Technologies Ltd, H2 2018
Pipeline by BeiGene Ltd, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by Elpiscience Biopharmaceuticals Co Ltd, H2 2018
Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Pipeline by GigaGen Inc, H2 2018
Pipeline by Incyte Corp, H2 2018
Pipeline by Interprotein Corp, H2 2018
Pipeline by Jounce Therapeutics Inc, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Symphogen A/S, H2 2018
Pipeline by TESARO Inc, H2 2018
Pipeline by Trellis Bioscience Inc, H2 2018
Dormant Projects, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Aurigene Discovery Technologies Ltd

BeiGene Ltd

Bristol-Myers Squibb Co

Eli Lilly and Co

Elpiscience Biopharmaceuticals Co Ltd

F. Hoffmann-La Roche Ltd

GigaGen Inc

Incyte Corp

Interprotein Corp

Jounce Therapeutics Inc

Novartis AG

Symphogen A/S

TESARO Inc

Trellis Bioscience Inc

I would like to order

Product name: Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/H0C9FFF360AEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H0C9FFF360AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970